English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduCHRYSALIS is a phase 1, open label, dose escalation and dose expansion trial evaluating amivantamab, a bispecific antibody with immune cell directing activity designed to engage two distinct driver pathways in non-small cell lung cancer: EGFR and MET. The novel therapy has already received Breakthrough Therapy Designation by the U.S. Food and Drug Administration based on preliminary efficacy data. New expanded data from the trial was published in the Journal of Clinical Oncology.
Mutations in the epidermal growth factor receptor (EGFR) gene are the most common targetable genomic drivers of non-small cell lung cancer. The role of EGFR is to help cells grow and divide. However, when EGFR is mutated, cell growth goes unchecked, allowing abnormal cells the opportunity to grow and multiply. There are several types of EGFR mutations. One type, EGFR exon 20 insertion (EGFR Ex20Ins), is seen in less than 10% of patients, but those with this specific EGFR mutation have poorer outcomes and don’t respond to FDA-approved targeted therapies, such as tyrosine kinase inhibitors. In addition, therapies are needed for patients whose tumors progress on experimental inhibitors for EGFR Ex20Ins.
“We have successfully developed targeted therapies for other types of EGFR mutations, but those therapies have less benefit for patients with the EGFR Ex20Ins mutation. Platinum-based chemotherapy remains the standard of care treatment for this group,” said Eric Haura, M.D., study author and associate center director of Clinical Science at Moffitt.
Accurate detection of EGFR Ex20Ins mutations is critical to identify patients with lung cancer who are most likely to respond to EGFR Ex20Ins targeted therapy. Smaller targeted assays may not identify all EGFR Ex20Ins mutations. The Moffitt STAR™ (Solid Tumor Actionable Result) genomics panel, a comprehensive next generation sequencing platform, precisely identifies patients with EGFR Ex20Ins mutations who may benefit from EGFR Ex20Ins targeted therapy.
The new expanded data of the CHRYSALIS study included 81 patients. The overall response rate, meaning the portion of patients who responded to the therapy, was 40%. Three patients had a complete response, meaning there was no evidence of disease, and 29 patients saw a partial response. The median duration of response was 11.1 months, with 20 patients having responses of at least six months or greater.
“The results from the study are encouraging, as we’re seeing durable responses among patients with a hard-to-treat subtype of non-small cell lung cancer,” said Haura. “In addition, we have seen responses in patients who have had prior therapy directed against these rare EGFR mutations.”
Ongoing studies with amivantamab continue at Moffitt for EGFR mutant and MET mutant lung cancer patients, and opportunities for this drug in other cancer types are being explored.
This study was funded by Janssen R&D LLC.
About Moffitt Cancer Center
Moffitt is dedicated to one lifesaving mission: to contribute to the prevention and cure of cancer. The Tampa-based facility is one of only 51 National Cancer Institute-designated Comprehensive Cancer Centers, a distinction that recognizes Moffitt’s scientific excellence, multidisciplinary research, and robust training and education. Moffitt’s expert nursing staff is recognized by the American Nurses Credentialing Center with Magnet® status, its highest distinction. With more than 7,500 team members, Moffitt has an economic impact in the state of $2.4 billion. For more information, call 1-888-MOFFITT (1-888-663-3488), visit MOFFITT.org, and follow the momentum on Facebook, Twitter, Instagram and YouTube.
###
